Evidence map›Paper›PMID 41473743›Full record

ArticleNeuro-oncology advances

Assessment of

Garry Ceccon, Michael Wollring, Isabelle Stetter, Jan-Michael Werner, Jana-Marie Peplinski, Jurij Rosen, Elena K Rosen, Manuel Kraft, Gereon R Fink, Karl-Josef Langen and 2 more

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Garry CecconDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID https://orcid.org/0009-0007-0510-4457
Michael WollringDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Isabelle StetterDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID https://orcid.org/0009-0007-1732-5759
Jan-Michael WernerDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-7147-4594
Jana-Marie PeplinskiDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Jurij RosenDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Elena K RosenDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Manuel KraftDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Gereon R FinkDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Karl-Josef LangenInstitute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
Philipp LohmannInstitute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.ORCID https://orcid.org/0000-0002-5360-046X
Norbert GalldiksDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-2485-1796

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their proficiency in predicting longer survival in patients with gliomas undergoing adjuvant temozolomide chemotherapy. Methods: In a previous study, 38 patients with newly diagnosed grade 4 gliomas according to the World Health Organisation classification underwent Results: According to the PET RANO 1.0 criteria, patients with Conclusions: Our data suggest that PET RANO 1.0 criteria identify survival differences between predefined groups.

Indexed as

alkylating chemotherapyamino acid PETmetabolic responders

Identifiers

PMID41473743
PMCPMC12746607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.